



Pioneering science delivers vital medicines™



About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing novel medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen is committed to advancing science to dramatically improve people's lives.

Reaching Patients Worldwide

Amgen medicines help patients around the world. The company has facilities or subsidiaries in the following locations:

United States (including Puerto Rico)

- California (Fremont, South San Francisco, Thousand Oaks)
- Colorado (Boulder, Longmont)
- Kentucky (Louisville)
- Massachusetts (Cambridge)
- Puerto Rico (Juncos)
- Rhode Island (West Greenwich)
- Washington (Bothell, Seattle)
- Washington, D.C.

Outside the United States

Australia	France	Lithuania	Slovakia
Austria	Germany	Luxembourg	Slovenia
Belgium	Greece	Mexico	Spain
Canada	Hong Kong	The Netherlands	Sweden
Czech Republic	Hungary	New Zealand	Switzerland
Denmark	India	Norway	United Arab Emirates
England	Ireland	Poland	
Estonia	Italy	Portugal	
Finland	Latvia	Russia	

AMGEN MISSION

To serve patients

AMGEN QUICK FACTS

Headquarters

Thousand Oaks, California

Staff

Approximately 17,500 worldwide

Stock Listing

NASDAQ: AMGN

Chairman and CEO

Kevin W. Sharer

2007 Financial Highlights

Total revenue: \$14.8 billion
 Product sales: \$14.3 billion
 R&D investment: \$3.1 billion

Address/Phone

One Amgen Center Drive
 Thousand Oaks, CA 91320-1799

Main: (805) 447-1000

Media: (805) 447-4587

Investors: (805) 447-1060

PRINCIPAL PRODUCTS

- Aranesp® (darbepoetin alfa)
- Enbrel® (etanercept)
- EPOGEN® (Epoetin alfa)
- Kepivance® (palifermin)
- Neulasta® (pegfilgrastim)
- NEUPOGEN® (Filgrastim)
- Sensipar® (cinacalcet HCl)
- Vectibix® (panitumumab)

For product information, including important safety information, visit www.amgen.com.

EXECUTIVE MANAGEMENT

Kevin W. Sharer

Chairman of the Board,
Chief Executive Officer and President

David Beier

Senior Vice President,
Global Government and Corporate Affairs

Fabrizio Bonanni

Executive Vice President,
Operations

Tom Flanagan

Senior Vice President and
Chief Information Officer

Brian M. McNamee

Senior Vice President,
Human Resources

George J. Morrow

Executive Vice President,
Global Commercial Operations

Robert A. Bradway

Executive Vice President
and Chief Financial Officer

Roger M. Perlmutter

Executive Vice President,
Research and Development

David J. Scott

Senior Vice President,
General Counsel, and Secretary

Commitment to Science

Being science-based is one of the Amgen core values and the essence of our culture. The company was founded to realize the potential of biotechnology, and our success always depends upon our ability to drive scientific innovation. Understanding human biology and the role that genes, and the proteins expressed by them, play in the disease process is the cornerstone of our method. Changing the practice of medicine for the benefit of patients is our ultimate objective.

Our commitment to science goes beyond the lab, clinic and manufacturing plant. We rely on the scientific method to drive continuous improvement in every aspect of our business. We value open inquiry and logical and rational processes; we seek to ask the right questions, collect and analyze the relevant data and make informed decisions.

An Interdisciplinary Approach to R&D

For more than 25 years, Amgen has been a leading innovator in the identification, isolation, production and use of human proteins as therapeutic agents. Today, Amgen scientists work at the cutting edge between the traditional disciplines of chemistry and cellular and molecular biology in an effort to discover and develop the medical breakthroughs of tomorrow. We focus on pioneering treatments for serious illness. Our R&D organization has cultivated expertise in multiple treatment modalities—large-molecule proteins, small molecules and antibodies—allowing us to choose the best target for attacking disease and to use the modality most likely to affect that target.

Amgen has research programs in inflammation, metabolic disorders and osteoporosis, neuroscience, oncology and hematology. Our research facilities are located in South San Francisco and Thousand Oaks, California; Cambridge, Massachusetts; Seattle, Washington; Burnaby, British Columbia, Canada; and Regensburg, Germany.

A Pioneer in Biotechnology Manufacturing

Assuring that Amgen medicines rapidly, reliably and safely reach patients is the charge of Amgen's manufacturing, process development, quality and distribution teams. From the beginning, the company's contributions to the field of biotechnological production of human therapeutics have been driven by a strong commitment to meet the needs of patients.

Manufacturing therapies based on proteins found in the human body is a complex and highly specialized activity. From process development and clinical manufacturing to full-scale therapeutic protein production, Amgen has built one of the industry's largest and most reliable operations.

Amgen operates manufacturing facilities in California, Colorado, Rhode Island, Washington and Puerto Rico.

INVESTOR INFORMATION

This fact sheet is a summary of more detailed disclosure that can be found in Amgen's filings with the U.S. Securities and Exchange Commission and its press releases. This fact sheet contains forward-looking statements that involve significant risks and uncertainties, discussion of which can be found in Amgen's most recent Forms 10-K, 10-Q, and 8-K and on www.amgen.com/investors. The information in this fact sheet is given as of the date below, and Amgen does not undertake any obligation to update any information in this document.

Advancing Science through Strategic Partnerships

With more than 100 active collaborations, Amgen is well-suited to be a partner of choice in the human therapeutics business. With the capabilities and financial strength of a large company, Amgen can offer partners the resources to support a potential new medicine as it advances from lab to clinic to marketplace. At the same time, Amgen retains the agility and decisiveness of a smaller biotech, with an unwavering commitment to science and patients.

Corporate Philanthropy

The causes Amgen supports, through the Amgen Foundation and other channels, reflect the company's efforts to elevate science, help patients and improve lives.

The Amgen Foundation

Since its founding in 1991, the Amgen Foundation has contributed nearly \$110 million to regional and national nonprofit groups that advance science education, improve quality of care and access for patients, and support vital community resources. The Foundation also matches Amgen staff member donations to eligible organizations. Since the inception of the Matching Gift Program in 1993, the Foundation has matched \$17 million in staff donations, resulting in more than \$34 million in support of worthy organizations across the United States and Puerto Rico.

Science Education

Amgen is inspiring and preparing the scientists of tomorrow through several signature science education programs, including Amgen Scholars, an eight-year, \$25 million program for college undergraduates; the Teach for America Amgen Fellows Program; the Amgen Bruce Wallace Biotechnology Lab Program; and the Amgen Award for Science Teaching Excellence.

Community Involvement

In the communities in which Amgen staff live and work, the company commits millions of dollars in charitable donations, and staff members devote thousands of hours of personal time, to programs and services that can make meaningful differences in people's lives.

Recent Recognition

On *Fortune* Magazine's 2007 list of "America's Most Admired Companies," Amgen ranked third in the biopharmaceutical industry.

Amgen ranked third in *Science's* "Top Employers" survey in October 2007.

Amgen was ranked second among large companies by *The Scientist* on its 2007 "Best Places to Work in Industry" survey.

Industry Affiliations

Amgen actively participates in industry organizations such as the Biotechnology Industry Organization, the Healthcare Leadership Council, and Pharmaceutical Research and Manufacturers of America.